1. Home
  2. GERN vs LYTS Comparison

GERN vs LYTS Comparison

Compare GERN & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • LYTS
  • Stock Information
  • Founded
  • GERN 1990
  • LYTS 1976
  • Country
  • GERN United States
  • LYTS United States
  • Employees
  • GERN N/A
  • LYTS N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • LYTS Building Products
  • Sector
  • GERN Health Care
  • LYTS Consumer Discretionary
  • Exchange
  • GERN Nasdaq
  • LYTS Nasdaq
  • Market Cap
  • GERN 740.5M
  • LYTS 700.9M
  • IPO Year
  • GERN 1996
  • LYTS N/A
  • Fundamental
  • Price
  • GERN $1.12
  • LYTS $18.34
  • Analyst Decision
  • GERN Buy
  • LYTS Strong Buy
  • Analyst Count
  • GERN 7
  • LYTS 2
  • Target Price
  • GERN $3.00
  • LYTS $27.50
  • AVG Volume (30 Days)
  • GERN 8.6M
  • LYTS 173.9K
  • Earning Date
  • GERN 11-05-2025
  • LYTS 11-06-2025
  • Dividend Yield
  • GERN N/A
  • LYTS 1.09%
  • EPS Growth
  • GERN N/A
  • LYTS 2.57
  • EPS
  • GERN N/A
  • LYTS 0.80
  • Revenue
  • GERN $183,403,000.00
  • LYTS $592,531,000.00
  • Revenue This Year
  • GERN $166.20
  • LYTS $5.91
  • Revenue Next Year
  • GERN $55.83
  • LYTS $8.03
  • P/E Ratio
  • GERN N/A
  • LYTS $22.98
  • Revenue Growth
  • GERN 522.13
  • LYTS 22.35
  • 52 Week Low
  • GERN $1.04
  • LYTS $13.77
  • 52 Week High
  • GERN $4.21
  • LYTS $25.50
  • Technical
  • Relative Strength Index (RSI)
  • GERN 40.96
  • LYTS 22.70
  • Support Level
  • GERN $1.04
  • LYTS $19.02
  • Resistance Level
  • GERN $1.28
  • LYTS $19.57
  • Average True Range (ATR)
  • GERN 0.07
  • LYTS 0.92
  • MACD
  • GERN 0.00
  • LYTS -0.49
  • Stochastic Oscillator
  • GERN 30.12
  • LYTS 5.11

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.

Share on Social Networks: